Clinical Trial Update: MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]

View source ↗

Summary

This is a Phase 2 trial evaluating axatilimab for idiopathic pulmonary fibrosis and it is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Axatilimab (axatilimab)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING